RxDoctor Payments Data

Christopher Johnson, MD

Internal Medicine · Athens, TXNPI 1942237078

Payments from drug & device makers

$724in general payments, 2019–2025

Across 44 payments — averaging $16.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$198
  • Lilly USA, LLC$108
  • AstraZeneca$58
  • Amgen$51
  • Radius Health, Inc.$50
  • Merck$48
  • plus $210 from 11 others

What the payments were for

  • Food & beverage$724100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$724 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$190,118
Medicare patients
314
Services billed
8,136

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin109$89,933
EliquisApixaban65$69,542
OzempicSemaglutide50$60,775
JanuviaSitagliptin Phosphate56$59,501
JanumetSitagliptin Phos/Metformin Hcl63$47,401
XareltoRivaroxaban44$45,938
TrulicityDulaglutide39$35,320
LinzessLinaclotide54$30,225
Soliqua 100-33Insulin Glargine/Lixisenatide16$16,627
MyrbetriqMirabegron28$15,049
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$13,010
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog22$12,980
MounjaroTirzepatide13$12,518
FarxigaDapagliflozin Propanediol16$10,079
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,134

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet, Janumet Xr$48$113,419135 claims
Boehringer IngelheimJardiance, Combivent Respimat$29$95,752121 claims
PfizerEliquis, Prempro, Premarin$13$79,83399 claims
Novo NordiskOzempic$198$60,77550 claims
Lilly USA, LLCTrulicity, Mounjaro$108$47,83852 claims
Johnson & JohnsonXarelto$17$45,93844 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta$16$15,89937 claims
AstraZenecaFarxiga, Symbicort$58$14,73235 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Athens

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →